Valeant seriously considering the sale of neuro assets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Valeant seriously considering the sale of neuro assets
October 20, 2015 10:22 AM EDT
Jefferies maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $224.00 (from $294.00), following the company's 3Q results. VRX reported revenues of $2.79B vs the Street's $2.78B. EPS was reported at $2.74 vs the Street's $2.72.
Analyst David Steinberg... More
October 20, 2015 6:46 AM EDT
Mizuho Securities reiterates a Neutral rating and $155.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's 3Q earnings report. Revenues of $2.80B beat consensus estimates of $2.79B and EPS of $2.74 came in $0.02 higher. Management raised full year revenue guidance to $11.0-$11.2B and... More
October 20, 2015 6:42 AM EDT
BMO Capital maintained an Outperform rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $265.00 (from $273.00), following the company's 3Q15 earnings results. VRX beat expectations for the quarter, however, the results showed that the legacy business had underperformed.
Analyst Alex Arfaei... More
